Five animal health companies you should know about


The animal health market originally emerged out of demand for certain segments in biotech and pharmaceuticals that are focused on improving animal life, including companion animals, such as dogs and cats, and farm animals, such as cattle and poultry. Now, there are many animal health companies trying to make a difference for animals.

With the world’s growing pet population also impacting demand, the veterinary market is thriving, growing very rapidly over the last few years. Even, the size of the animal health market is expected to be worth around $80.9 billion in 2028, compared to around $46.6 billion in 2020.

In this article, listed in alphabetical order, we look at five of the top animal health companies trying to improve the health of various animals by developing products such as vaccines, pain relief and antiparasitic treatments.

Something Healthy Animal

Ceva Sante Animale is a French animal health company founded in 1999, and researches, develops, manufactures and supplies vaccines, pharmaceutical drugs and other animal health products, together with equipment, training, technical support and specialized services for professionals veterinarians and humans. caring for animals around the world.

The company says its business is organized around four areas, which are specific to the types of animals the company makes its products for. These are: poultry, swine, ruminants and companion animals.

Although the company did not start out that way, it is now committed to preventive health, believing that vaccines play an important role in promoting the rational use of antibiotics, which is essential for protecting human and animal health. Now, 40% of the company’s business is dedicated to vaccines, compared to only 25% in 2010.

Road Animal Health

American foulbrood (AFB) is one of the most damaging and fatal diseases known to affect honey bee broods, weakening and killing honey bee colonies. It is highly contagious and is caused by bacteria Paenibacillus larvae. Traditionally, it has been treated with antibiotics, which can negatively affect honey bees, such as antibiotic resistance and disruption of the honey bee microbiome and overall health of the hive.

However, Dalan Animal Health hopes to change that, and, earlier this year, a world first, the company’s honeybee vaccine to treat AFB received a conditional license from the US Department of Agriculture (USDA), which could prevent AFB outbreaks and eliminate the need for antibiotics.

Dalan’s vaccine contains dead, intact cells P. larva bacteria, and works through transgenerational priming, in which the parent animal passes immune modulators to the next generation of larvae before they hatch.

In this case, the vaccine is administered orally after being mixed into the royal jelly which is fed to the queen bee. The vaccine piece is then deposited in the queen’s ovary, where her eggs are exposed to the vaccine, triggering a future immune response against the bacteria.


Elanco is a global leader in animal health, and is dedicated to innovating and delivering products and services to prevent and treat disease in livestock and pets.

For pets, the company is focused on developing solutions that will treat pain and prevent disease, improve and prolong quality of life, and increase the type of care pets receive. Some of its products include: ATOPICA, for cat allergic dermatitis; Canine Parvovirus Monoclonal Antibody, which targets canine parvovirus (CPV); and Seresto for Dogs, to prevent ticks and fleas.

As for livestock, the company supports disease prevention, control and treatment. Examples of products for livestock include: Baytril100, which is a single dose fluoroquinolone for treating bovine respiratory disease (BRD) in cattle; Para Shield, namely glasserella (Haemophilus) vaccine in pigs; and Pili Shield to protect piglets from E. coli, through bypassing maternal antibodies.

The company has a pipeline of more than 100 active programs for many different species.


While immunotherapy has been used successfully to treat diseases in humans, it is a bit behind when it comes to treating conditions in dogs.

Animal health company Vetigenics aims to change that by developing a fully canine antibody-based immunotherapy to treat cancer, as well as infectious diseases and other chronic conditions.

The company has a phage display library estimated to contain more than 40 billion independent single chain fragment (scFv) variables, or CANIBODIES. Dog antibody fragments are fully precise, highly efficacious and non-immunogenic. Using its platform, companies can quickly isolate multiple CANIBODIES during the first stages of development, before being selected for their desired development functionality and properties.

CANIBODIES can be engineered into several delivery formats, such as full-length canine IgG (monoclonal antibody) or CAR-T therapy. With its platform, Vetigenics has built a portfolio of CANIBODY immunomodulators that are in various stages of production to treat immune-mediated cancer, infections, and chronic diseases.


Founded in 1952, American animal health company Zoetis left Pfizer, and is the world’s largest manufacturer of vaccinations and pet medicines. It has become the face of the animal health enterprise market, inventing, developing, manufacturing, and commercializing vaccines, drugs, and diagnostics for a variety of different animals, including dogs, cats, horses, cattle, and even fish.

Some of the company’s milestones and achievements in animal health include the fact that it has more than 300 product lines across eight animal species, 14 blockbuster animal health products that generate over $100 million in annual sales, and approximately 1,000 new products and lifestyle innovations that have been introduced. in the last five years.

Some of Zoetis’ products include APOQUEL, which has become a standard in dermatological care for veterinarians, Revolution PLUS, which is a broad spectrum feline parasite inhibitor, and Librela, which helps relieve pain in cats and dogs with osteoarthritis.

Through the Center for Transboundary and Emerging Diseases, the company also manages its response to infectious disease outbreaks, working with governments, health organizations and the animal and livestock community to identify infectious disease threats early and develop solutions such as vaccines to prevent their spread.


Source link

Related Articles

Back to top button